BRAF and colonic neoplasm: It has previously been shown that BRAF mutated RKO colon cancer cells have remarkably higher activities and protein expression levels of SphK1 and SphK2 in comparison to several other colon cancer cell lines harbouring wild-type BRAF, and that they exhibit the least sensitivity to oxaliplatin [4].